Chardan Capital Weighs in on Prime Medicine FY2025 Earnings

Prime Medicine, Inc. (NYSE:PRME - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings estimates for Prime Medicine in a report released on Monday, March 10th. Chardan Capital analyst G. Livshits forecasts that the company will earn ($1.25) per share for the year. Chardan Capital has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share.

Prime Medicine (NYSE:PRME - Get Free Report) last posted its quarterly earnings data on Friday, March 7th. The company reported ($1.65) earnings per share for the quarter. During the same period in the prior year, the business posted ($2.18) EPS.

A number of other equities research analysts have also recently commented on PRME. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Prime Medicine in a research report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and issued a $12.00 target price on shares of Prime Medicine in a research report on Friday, February 28th. StockNews.com upgraded shares of Prime Medicine to a "sell" rating in a research report on Tuesday, February 11th. Citizens Jmp upgraded shares of Prime Medicine to a "strong-buy" rating in a research report on Tuesday, December 10th. Finally, JMP Securities initiated coverage on shares of Prime Medicine in a research report on Tuesday, December 10th. They issued an "outperform" rating and a $10.00 target price for the company. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.13.

Remove Ads

Prime Medicine Trading Down 2.2 %

NYSE:PRME traded down $0.04 during trading hours on Thursday, reaching $1.75. 1,005,170 shares of the company were exchanged, compared to its average volume of 1,089,175. The stock's 50-day moving average is $2.68 and its 200-day moving average is $3.26. The firm has a market cap of $229.53 million, a PE ratio of -0.85 and a beta of 1.85. Prime Medicine has a twelve month low of $1.71 and a twelve month high of $8.27.

Institutional Investors Weigh In On Prime Medicine

A number of hedge funds have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new position in Prime Medicine during the third quarter worth about $383,000. Intech Investment Management LLC purchased a new position in Prime Medicine during the third quarter worth about $55,000. Corsair Capital Management L.P. purchased a new position in Prime Medicine during the third quarter worth about $77,000. PEAK6 Investments LLC boosted its stake in Prime Medicine by 32.4% during the third quarter. PEAK6 Investments LLC now owns 45,013 shares of the company's stock worth $174,000 after buying an additional 11,013 shares during the period. Finally, Walleye Capital LLC purchased a new position in Prime Medicine during the third quarter worth about $419,000. Hedge funds and other institutional investors own 70.37% of the company's stock.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.